OTCMKTS:TBUFF

Tribute Pharmaceuticals Canada (TBUFF) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
50,100 shs
Average Volume
71,826 shs
Market Capitalization
$105.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TBUFF stock logo

About Tribute Pharmaceuticals Canada Stock (OTCMKTS:TBUFF)

Tribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial.

TBUFF Stock News Headlines

The Crypto 9-5 Escape Plan
A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.
Tribute Pharmaceuticals Canada Inc (TRX)
See More Headlines
Receive TBUFF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tribute Pharmaceuticals Canada and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/31/2014
Today
5/12/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
OTCMKTS:TBUFF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$105.76 million
Optionable
Not Optionable
Beta
N/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Arnold Tenney (Age 70)
    Chairman of the Board
  • Robert Harris (Age 57)
    President, Chief Executive Officer, Director
  • Scott Langille (Age 56)
    Chief Financial Officer, Director
  • Janice M. Clarke (Age 52)
    Vice President - Finance and Administration
  • Steven H. Goldman (Age 57)
    Independent Director
  • John M. Gregory (Age 60)
    Independent Director
  • John J. Kime (Age 70)
    Independent Director
  • Francis Martin Thrasher (Age 61)
    Independent Director

TBUFF Stock Analysis - Frequently Asked Questions

How were Tribute Pharmaceuticals Canada's earnings last quarter?

Tribute Pharmaceuticals Canada Inc. (OTCMKTS:TBUFF) announced its quarterly earnings data on Monday, March, 31st. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.02) by $0.01. The business earned $2.90 million during the quarter.

How do I buy shares of Tribute Pharmaceuticals Canada?

Shares of TBUFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:TBUFF) was last updated on 5/12/2024 by MarketBeat.com Staff

From Our Partners